Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on company's unique patented drug testing process. Psychemedics Corporation strongly believes its drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods.
Company profile
Ticker
PMD
Exchange
Website
CEO
Raymond C. Kubacki
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Psychemedics International, LLC • Psychemedics Laboratórios Ltda • (owned jointly by Psychemedics Corporation • and Psychemedics International ...
IRS number
581701987
PMD stock data
Press releases
Psychemedics Announces Two New Director Nominees for its 2022 Annual Meeting of Stockholders and Director Walter S. Tomenson, Jr.'s Retirement after More than 20 Years of Dedicated Service
9 Jun 22
Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend
10 May 22
Psychemedics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 22
Calendar
11 May 22
26 Jun 22
31 Dec 22
Financial summary
| Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 2.13M | 2.13M | 2.13M | 2.13M | 2.13M | 2.13M |
| Cash burn (monthly) | (no burn) | 5.25K | (no burn) | 72.42K | (no burn) | (no burn) |
| Cash used (since last report) | n/a | 15.09K | n/a | 208.11K | n/a | n/a |
| Cash remaining | n/a | 2.11M | n/a | 1.92M | n/a | n/a |
| Runway (months of cash) | n/a | 402.3 | n/a | 26.5 | n/a | n/a |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 20 May 22 | Raymond C Kubacki JR | Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 0 | 20,000 | 0 | 252,587 |
| 20 May 22 | Andrew Limbek | Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 0 | 7,000 | 0 | 13,863 |
| 20 May 22 | Michael I Schaffer | Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 0 | 5,000 | 0 | 37,626 |
| 20 May 22 | Andrew Reynolds | Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 0 | 12,000 | 0 | 14,000 |
| 20 May 22 | Charles M Doucot | Common Stock, $.005 Par Value | Grant | Acquire A | No | No | 0 | 11,000 | 0 | 39,025 |
Institutional ownership, Q1 2022
27.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 24 |
| Opened positions | 2 |
| Closed positions | 3 |
| Increased positions | 6 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 10.43M |
| Total shares | 1.53M |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Renaissance Technologies | 341.42K | $2.36M |
| Crawford Investment Counsel | 266.5K | $1.84M |
| Vanguard | 247.34K | $1.71M |
| RBF Capital | 144.23K | $996K |
| Invenomic Capital Management | 135.63K | $769K |
| BLK Blackrock | 88.42K | $609K |
| Ancora Advisors | 80.73K | $557K |
| Dimensional Fund Advisors | 60.31K | $419K |
| Wealth Effects | 40K | $276K |
| Geode Capital Management | 34.62K | $240K |
Financial report summary
?Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
avoid, binding, broad, calendar, Central, certification, customary, deny, devoted, dispersed, District, enforceable, Enma, event, exact, exceed, Factoring, February, found, fuel, half, hour, hourly, immaterial, lack, lawsuit, level, main, matter, meal, mediation, membership, Memorandum, merit, MOU, opt, pertaining, prior, Private, protracted, release, rest, revoke, Sagastume, settle, shipping, similar, size, slight, soaring, sought, subcommittee, successor, Supplementary, transportation, Understanding, variable, wage, wrongdoing
Removed:
adjustment, administered, Administration, amending, annum, application, applied, approach, ASC, ASU, Bank, beginning, borrowed, Brazilian, breakdown, clarifying, comparable, consistent, creation, currency, detail, distributor, driver, duration, entitled, established, evidenced, FASB, full, GAAP, geographic, greater, implementation, improve, individual, involve, issued, January, job, margin, maturity, package, percent, permitted, professional, promissory, proposed, prospective, reduced, region, removing, resulting, retrospective, SBA, segment, simplify, Simplifying, Small, standard, Topic, travel, unpaid, update
Financial reports
Current reports
8-K
Entry into a Material Definitive Agreement
9 Jun 22
8-K
Psychemedics Corporation Reports First Quarter 2022 Financial Results and Declares Increased Cash Dividend
10 May 22
8-K
Psychemedics Corporation Reports Fourth Quarter and Full Year 2021 Financial Results
29 Mar 22
8-K
Psychemedics Corporation Welcomes Drew Reynolds to Its Board of Directors and Announces the Retirement of Harry Connick From His Director Role
22 Mar 22
8-K
Regulation FD Disclosure
10 Mar 22
8-K
Departure of Directors or Certain Officers
3 Feb 22
8-K
Psychemedics Corporation Declares Cash Dividend
10 Dec 21
8-K
Psychemedics Corporation Reports Stronger Revenue, Operating Profit and Earnings Growth in Third Quarter 2021
12 Nov 21
8-K
Other Events
23 Sep 21
8-K
Psychemedics Corporation Reports Stronger Second Quarter 2021 Financial Results
10 Aug 21
Registration and prospectus
S-8
Registration of securities for employees
25 May 21
S-8
Registration of securities for employees
13 Aug 19
S-8
Registration of securities for employees
31 May 16
S-8 POS
Registration of securities for employees (post-effective amendment)
1 Mar 16
S-8
Registration of securities for employees
25 May 11
POS AM
Prospectus update (post-effective amendment)
3 Feb 11
POS AM
Prospectus update (post-effective amendment)
3 Feb 11
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 11
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 11
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Jan 11
Ownership
SC 13D/A
PSYCHEMEDICS / Kamin Peter ownership change
10 Jun 22
4
PSYCHEMEDICS / Robyn C Davis ownership change
24 May 22
4
PSYCHEMEDICS / FRED J WEINERT ownership change
24 May 22
4
PSYCHEMEDICS / WALTER S TOMENSON ownership change
24 May 22
4
PSYCHEMEDICS / Andrew Reynolds ownership change
24 May 22
4
PSYCHEMEDICS / Charles M Doucot ownership change
24 May 22
4
PSYCHEMEDICS / Andrew Limbek ownership change
24 May 22
4
PSYCHEMEDICS / MICHAEL I SCHAFFER ownership change
24 May 22
4
PSYCHEMEDICS / RAYMOND C KUBACKI JR ownership change
24 May 22
4
PSYCHEMEDICS / Andrew Limbek ownership change
17 May 22
Patents
Utility
Homogeneous Enzyme Immunoassay for Keratinized Structures
21 Apr 22
This disclosure relates to methods and kits for determining the presence and/or amount of one or more analytes in a keratinized structure (e.g., hair) sample.
Utility
Homogeneous Enzyme Immunoassay for Keratinized Structures
18 Feb 21
This disclosure relates to methods and kits for determining the presence and/or amount of one or more analytes in a keratinized structure (e.g., hair) sample.
Utility
Solid phase multi-analyte assay
20 Jan 20
Compositions and methods for detecting the presence and/or amount of one or more analytes, including analytes such as drugs of abuse, are provided.
Reddit threads
Daily Discussion Thread - May 26th, 2022
26 May 22
Daily Discussion Thread - May 25th, 2022
25 May 22
Daily Discussion Thread - May 24th, 2022
24 May 22
Daily Discussion Thread - May 23rd, 2022
23 May 22
Daily Discussion Thread - May 9th, 2022
9 May 22
Daily Discussion Thread - May 6th, 2022
6 May 22
Daily Discussion Thread - March 29th, 2022
29 Mar 22
Daily Discussion Thread - March 28th, 2022
28 Mar 22
Daily Discussion Thread - March 22nd, 2022
22 Mar 22
Daily Discussion Thread - March 21st, 2022
21 Mar 22